- Home
- RNR vs QGEN Comparison
RNR vs QGEN Comparison
Compare RNR & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RNR | QGEN |
|---|---|---|
| Founded | 1993 | 1986 |
| Country | Bermuda | Netherlands |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 10.7B |
| IPO Year | 1995 | 1996 |
Fundamental Metrics
Financial Performance| Metric | RNR | QGEN |
|---|---|---|
| Price | $262.82 | $47.78 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 7 |
| Target Price | ★ $291.73 | $50.68 |
| AVG Volume (30 Days) | 439.2K | ★ 1.3M |
| Earning Date | 10-28-2025 | 11-04-2025 |
| Dividend Yield | 0.61% | ★ 3.16% |
| EPS Growth | N/A | ★ 331.20 |
| EPS | ★ 34.70 | 1.84 |
| Revenue | ★ $12,214,870,000.00 | $2,070,781,000.00 |
| Revenue This Year | N/A | $7.37 |
| Revenue Next Year | N/A | $5.65 |
| P/E Ratio | ★ $7.53 | $26.16 |
| Revenue Growth | N/A | ★ 5.32 |
| 52 Week Low | $219.00 | $37.63 |
| 52 Week High | $290.78 | $51.88 |
Technical Indicators
Market Signals| Indicator | RNR | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 53.11 | 60.62 |
| Support Level | $251.60 | $43.59 |
| Resistance Level | $263.87 | $48.69 |
| Average True Range (ATR) | 4.86 | 0.73 |
| MACD | -0.78 | 0.51 |
| Stochastic Oscillator | 55.05 | 83.08 |
Price Performance
Historical ComparisonAbout RNR RenaissanceRe Holdings Ltd.
RenaissanceRe Holdings Ltd provides reinsurance and insurance solutions and related services. The company's core products include property, casualty and specialty reinsurance. Revenue is derived from three sources: net premiums earned from the insurance and insurance products sold; net investment income from the investment of capital funds and cash; and other income from the company's joint ventures, advisory services, and other items. The reportable segments of the company are the Property segment which includes catastrophe and other property reinsurance, and the Casualty and Specialty segment which is comprised of casualty and specialty reinsurance. It derives a majority of its revenue from the Casualty and specialty segment.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).